Moderate to Severe Osteoarthritis

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BT
1 program
1
SM04690, 0.03mg/2mLPhase 11 trial
Active Trials
NCT02095548CompletedEst. Sep 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Biosplice TherapeuticsSM04690, 0.03mg/2mL

Clinical Trials (1)

Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

Start: Mar 2014Est. completion: Sep 2015
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space